PGBD5 promotes site-specific oncogenic mutations in human tumors

Autor: Henssen, AG, Koche, R, Zhuang, J, Jiang, E, Reed, C, Eisenberg, A, Still, E, MacArthur, IC, Rodríguez-Fos, E, Gonzalez, S, Puiggròs, M, Blackford, AN, Mason, CE, De Stanchina, E, Gönen, M, Emde, A-K, Shah, M, Arora, K, Reeves, C, Socci, ND, Perlman, E, Antonescu, CR, Roberts, CWM, Steen, H, Mullen, E, Jackson, SP, Torrents, D, Weng, Z, Armstrong, SA, Kentsis, A

Genomic rearrangements are a hallmark of human cancers. Here, we identify the piggyBac transposable element derived 5 (PGBD5) gene as encoding an active DNA transposase expressed in the majority of childhood solid tumors, including lethal rhabdoid tu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fc1dbeb3d485d24124d71dc7ec5d0bab

Reconstructing extrachromosomal DNA structural heterogeneity from long-read sequencing data using Decoil.

Autor: Giurgiu M; Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany; madalina.giurgiu@charite.de anton.henssen@charite.de knut.reinert@fu-berlin.de.; Experimental and Clinical Research Center of the Max Delbrück Center and Charité Berlin, 13125 Berlin, Germany.; Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany.; Freie Universität Berlin, 14195 Berlin, Germany., Wittstruck N; Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany.; Experimental and Clinical Research Center of the Max Delbrück Center and Charité Berlin, 13125 Berlin, Germany.; Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany., Rodriguez-Fos E; Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany.; Experimental and Clinical Research Center of the Max Delbrück Center and Charité Berlin, 13125 Berlin, Germany.; Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany., Chamorro González R; Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany.; Experimental and Clinical Research Center of the Max Delbrück Center and Charité Berlin, 13125 Berlin, Germany.; Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany.; Max Delbrück Center for Molecular Medicine, 13125 Berlin, Germany., Brückner L; Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany.; Experimental and Clinical Research Center of the Max Delbrück Center and Charité Berlin, 13125 Berlin, Germany.; Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany.; Max Delbrück Center for Molecular Medicine, 13125 Berlin, Germany., Krienelke-Szymansky A; Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany.; Experimental and Clinical Research Center of the Max Delbrück Center and Charité Berlin, 13125 Berlin, Germany.; Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany., Helmsauer K; Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany.; Experimental and Clinical Research Center of the Max Delbrück Center and Charité Berlin, 13125 Berlin, Germany.; Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany., Hartebrodt A; Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany., Euskirchen P; German Cancer Consortium (DKTK), partner site Berlin, a partnership between DKFZ and Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany.; Department of Neuropathology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 13353 Berlin, Germany., Koche RP; Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA., Haase K; Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany.; Experimental and Clinical Research Center of the Max Delbrück Center and Charité Berlin, 13125 Berlin, Germany.; Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany., Reinert K; Freie Universität Berlin, 14195 Berlin, Germany., Henssen AG; Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany; madalina.giurgiu@charite.de anton.henssen@charite.de knut.reinert@fu-berlin.de.; Experimental and Clinical Research Center of the Max Delbrück Center and Charité Berlin, 13125 Berlin, Germany.; Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany.; Max Delbrück Center for Molecular Medicine, 13125 Berlin, Germany.

Publikováno v: Genome research [Genome Res] 2024 Oct 11; Vol. 34 (9), pp. 1355-1364. Date of Electronic Publication: 2024 Oct 11.

Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models.

Autor: Pusch FF; Experimental and Clinical Research Center (ECRC) of the MDC and Charité Berlin, Berlin, Germany.; Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany., Dorado García H; Experimental and Clinical Research Center (ECRC) of the MDC and Charité Berlin, Berlin, Germany.; Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany., Xu R; Experimental and Clinical Research Center (ECRC) of the MDC and Charité Berlin, Berlin, Germany.; Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany., Gürgen D; Experimental Pharmacology and Oncology (EPO), Berlin, Germany., Bei Y; Experimental and Clinical Research Center (ECRC) of the MDC and Charité Berlin, Berlin, Germany.; Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany., Brückner L; Experimental and Clinical Research Center (ECRC) of the MDC and Charité Berlin, Berlin, Germany.; Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.; Max-Delbrück-Centrum für Molekulare Medizin (BIMSB/BIH), Berlin, Germany., Röefzaad C; Experimental and Clinical Research Center (ECRC) of the MDC and Charité Berlin, Berlin, Germany.; Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany., von Stebut J; Experimental and Clinical Research Center (ECRC) of the MDC and Charité Berlin, Berlin, Germany.; Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany., Bardinet V; Experimental and Clinical Research Center (ECRC) of the MDC and Charité Berlin, Berlin, Germany., Chamorro Gonzalez R; Experimental and Clinical Research Center (ECRC) of the MDC and Charité Berlin, Berlin, Germany.; Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany., Eggert A; Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany., Schulte JH; Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.; Department of Pediatric Oncology and Hematology, University Hospital Tübingen, Tübingen, Germany., Hundsdörfer P; Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.; Helios Klinikum Berlin-Buch, Berlin, Germany., Seifert G; Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany., Haase K; Experimental and Clinical Research Center (ECRC) of the MDC and Charité Berlin, Berlin, Germany., Schäfer BW; University Children's Hospital, Zurich, Switzerland., Wachtel M; University Children's Hospital, Zurich, Switzerland., Kühl AA; iPATH.Berlin-Core Unit Immunopathology for Experimental Models, Charité Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany., Ortiz MV; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York City, New York., Wengner AM; Bayer AG, Berlin, Germany., Scheer M; Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany., Henssen AG; Experimental and Clinical Research Center (ECRC) of the MDC and Charité Berlin, Berlin, Germany.; Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.; Max-Delbrück-Centrum für Molekulare Medizin (BIMSB/BIH), Berlin, Germany.; Berlin Institute of Health, Berlin, Germany.; German Cancer Consortium (DKTK), partner site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany.

Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2024 Apr 02; Vol. 23 (4), pp. 507-519.

Genetic determinants of micronucleus formation in vivo.

Autor: Adams DJ; Wellcome Sanger Institute, Cambridge, UK. da1@sanger.ac.uk., Barlas B; UK Dementia Research Institute at the University of Cambridge, University of Cambridge, Cambridge, UK.; Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK., McIntyre RE; Wellcome Sanger Institute, Cambridge, UK., Salguero I; The Gurdon Institute and Department of Biochemistry, University of Cambridge, Cambridge, UK., van der Weyden L; Wellcome Sanger Institute, Cambridge, UK., Barros A; Wellcome Sanger Institute, Cambridge, UK.; The Gurdon Institute and Department of Biochemistry, University of Cambridge, Cambridge, UK., Vicente JR; UK Dementia Research Institute at the University of Cambridge, University of Cambridge, Cambridge, UK.; Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK., Karimpour N; UK Dementia Research Institute at the University of Cambridge, University of Cambridge, Cambridge, UK.; Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK., Haider A; UK Dementia Research Institute at the University of Cambridge, University of Cambridge, Cambridge, UK.; Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK., Ranzani M; Wellcome Sanger Institute, Cambridge, UK., Turner G; Wellcome Sanger Institute, Cambridge, UK., Thompson NA; Wellcome Sanger Institute, Cambridge, UK., Harle V; Wellcome Sanger Institute, Cambridge, UK., Olvera-León R; Wellcome Sanger Institute, Cambridge, UK., Robles-Espinoza CD; Wellcome Sanger Institute, Cambridge, UK.; Laboratorio Internacional de Investigación Sobre el Genoma Humano, Universidad Nacional Autónoma de México, Santiago de Querétaro, México., Speak AO; Wellcome Sanger Institute, Cambridge, UK., Geisler N; Wellcome Sanger Institute, Cambridge, UK.; The Gurdon Institute and Department of Biochemistry, University of Cambridge, Cambridge, UK., Weninger WJ; Division of Anatomy, MIC, Medical University of Vienna, Wien, Austria., Geyer SH; Division of Anatomy, MIC, Medical University of Vienna, Wien, Austria., Hewinson J; Wellcome Sanger Institute, Cambridge, UK., Karp NA; Wellcome Sanger Institute, Cambridge, UK., Fu B; Wellcome Sanger Institute, Cambridge, UK., Yang F; Wellcome Sanger Institute, Cambridge, UK., Kozik Z; Functional Proteomics Group, Chester Beatty Laboratories, The Institute of Cancer Research, London, UK., Choudhary J; Functional Proteomics Group, Chester Beatty Laboratories, The Institute of Cancer Research, London, UK., Yu L; Functional Proteomics Group, Chester Beatty Laboratories, The Institute of Cancer Research, London, UK., van Ruiten MS; Division of Cell Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Rowland BD; Division of Cell Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Lelliott CJ; Wellcome Sanger Institute, Cambridge, UK., Del Castillo Velasco-Herrera M; Wellcome Sanger Institute, Cambridge, UK., Verstraten R; Wellcome Sanger Institute, Cambridge, UK., Bruckner L; Experimental and Clinical Research Center (ECRC) of the MDC and Charité Berlin, Berlin, Germany.; Max-Delbrück-Centrum für Molekulare Medizin, Berlin, Germany., Henssen AG; Experimental and Clinical Research Center (ECRC) of the MDC and Charité Berlin, Berlin, Germany.; Max-Delbrück-Centrum für Molekulare Medizin, Berlin, Germany.; Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.; German Cancer Consortium (DKTK), partner site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany., Rooimans MA; Department of Human Genetics, Section of Oncogenetics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands., de Lange J; Department of Human Genetics, Section of Oncogenetics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands., Mohun TJ; Division of Developmental Biology, MRC, National Institute for Medical Research, London, UK., Arends MJ; Division of Pathology, Cancer Research UK Scotland Centre, Institute of Genetics & Cancer The University of Edinburgh, Edinburgh, UK., Kentistou KA; MRC Epidemiology Unit, Wellcome-MRC Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge, UK., Coelho PA; Department of Genetics, University of Cambridge, Cambridge, UK., Zhao Y; UK Dementia Research Institute at the University of Cambridge, University of Cambridge, Cambridge, UK.; Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK., Zecchini H; Metabolic Research Laboratory, Wellcome-MRC Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge, UK., Perry JRB; MRC Epidemiology Unit, Wellcome-MRC Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge, UK.; Metabolic Research Laboratory, Wellcome-MRC Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge, UK., Jackson SP; The Gurdon Institute and Department of Biochemistry, University of Cambridge, Cambridge, UK.; Cancer Research UK Cambridge Institute, Cambridge, UK., Balmus G; Wellcome Sanger Institute, Cambridge, UK. gb318@cam.ac.uk.; UK Dementia Research Institute at the University of Cambridge, University of Cambridge, Cambridge, UK. gb318@cam.ac.uk.; Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK. gb318@cam.ac.uk.; The Gurdon Institute and Department of Biochemistry, University of Cambridge, Cambridge, UK. gb318@cam.ac.uk.; Department of Molecular Neuroscience, Transylvanian Institute of Neuroscience, Cluj-Napoca, Romania. gb318@cam.ac.uk.

Publikováno v: Nature [Nature] 2024 Mar; Vol. 627 (8002), pp. 130-136. Date of Electronic Publication: 2024 Feb 14.

Doxorubicin Changes the Spatial Organization of the Genome around Active Promoters.

Autor: Stefanova ME; Development and Disease Research Group, Max Planck Institute for Molecular Genetics, 14195 Berlin, Germany.; Institute for Medical and Human Genetics, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany., Ing-Simmons E; MRC London Institute of Medical Sciences, Du Cane Road, London W12 0NN, UK.; Institute of Clinical Sciences, Faculty of Medicine, Imperial College London, London SW7 2AZ, UK., Stefanov S; Berlin Institute for Molecular and Systems Biology, Max Delbrück Center for Molecular Medicine, 13125 Berlin, Germany.; Department of Biology, Chemistry, and Pharmacology, Institute of Biochemistry, Freie Universität Berlin, 14163 Berlin, Germany., Flyamer I; Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, 4058 Basel, Switzerland., Dorado Garcia H; Experimental and Clinical Research Center (ECRC) of the MDC and Charité Berlin, 13125 Berlin, Germany.; Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, 13353 Berlin, Germany.; Max Delbrück Center for Molecular Medicine, 13125 Berlin, Germany., Schöpflin R; Development and Disease Research Group, Max Planck Institute for Molecular Genetics, 14195 Berlin, Germany.; Institute for Medical and Human Genetics, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany., Henssen AG; Experimental and Clinical Research Center (ECRC) of the MDC and Charité Berlin, 13125 Berlin, Germany.; Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, 13353 Berlin, Germany.; Max Delbrück Center for Molecular Medicine, 13125 Berlin, Germany.; German Cancer Consortium (DKTK), Partner Site Berlin, and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany., Vaquerizas JM; MRC London Institute of Medical Sciences, Du Cane Road, London W12 0NN, UK.; Institute of Clinical Sciences, Faculty of Medicine, Imperial College London, London SW7 2AZ, UK., Mundlos S; Development and Disease Research Group, Max Planck Institute for Molecular Genetics, 14195 Berlin, Germany.; Institute for Medical and Human Genetics, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany.; Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.

Publikováno v: Cells [Cells] 2023 Aug 04; Vol. 12 (15). Date of Electronic Publication: 2023 Aug 04.